Skip to main content

Advertisement

Table 3 12/24-month persistence rates and 95% confidence intervals (CI) for BTs psoriasis therapy

From: Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

  Total BT-naïve
ADL IFX SCK UST ADL IFX SCK UST
Number of patients 42 52 21 90 37 48 13 79
12-month persistence rate ± 95% CI 45.9% ± 15.5% 53.1% ± 14.7% 74.2% (95% CI not available) 79.8% ± 9.1% 46.8% ± 16.6% 53.0% ± 14.9% 55.4% (95% CI not available) 79.4% ± 9.9%
24-month persistence rate ± 95% CI 45.9 ± 15.5% 41.1% ± 15.4% 74.2% (95% CI not available) 73.4% ± 10.9% 46.8 ± 16.6% 41.0% ± 15.5% 55.4% (95% CI not available) 71.9 ± 12.2%
p-value of log-rank test (versus UST) < 0.001 < 0.001 0.254 < 0.001 < 0.001 0.006
p-value of wilcoxon test (versus UST) < 0.001 0.001 0.163 < 0.001 0.001 0.004
  1. ADL Adalimumab, IFX Infliximab, SCK Secukinumab, UST Ustekinumab. 95% CI of SCK was not available because of too small number of patients